Cargando…
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma
BACKGROUND: Transarterial chemoembolisation (TACE) has not been shown to be superior to bland embolisation (TAE) for treatment of hepatocellular carcinoma (HCC). METHODS: We conducted a randomised phase II/III trial in patients with untreated HCC. Patients were randomised to TAE with polyvinyl alcoh...
Autores principales: | Meyer, T, Kirkwood, A, Roughton, M, Beare, S, Tsochatzis, E, Yu, D, Davies, N, Williams, E, Pereira, S P, Hochhauser, D, Mayer, A, Gillmore, R, O'Beirne, J, Patch, D, Burroughs, A K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619271/ https://www.ncbi.nlm.nih.gov/pubmed/23449352 http://dx.doi.org/10.1038/bjc.2013.85 |
Ejemplares similares
-
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
por: Kadalayil, L., et al.
Publicado: (2013) -
Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Lawson, Alexander, et al.
Publicado: (2023) -
Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival—prospective interventional study
por: Bessar, Ahmed A., et al.
Publicado: (2021) -
Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020) -
Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort
por: Papastergiou, V, et al.
Publicado: (2014)